News

The drugs in development include Biogen’s controversial treatment for Alzheimer’s disease and three new drugs for atopic dermatitis.

The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.

Teva is making the first generic version of Absorica (isotretinoin), a drug for the treatment of severe acne.

Young adults did not have significantly better sleep when using blue light filters on their smartphones in the hour before bed, according to a new study.

There’s no going back to the ways of working before COVID-19’s arrival, say many in the industry. Insurers and PBMs are reducing their footprint as work becomes part remote, part in person.

Copay accumulators are a common feature in health insurance plans sold on the ACA exchanges, according to a recent report from an AIDS advocacy group that wants the Biden administration to reverse a decision made by the Trump administration that allowed continued use of accumulators.

Emphasizing data efficiencies and quality will benefit payers and providers — and patients.

Researchers find that it is quite the opposite.

The study, which will be presented next week during the 70th American College of Cardiology Scientific Session, is the first to examine how chest pain is managed among adults who are too young for Medicare.

Deaths by suicide and by substance use disorders have reached epidemic proportions, creating the tragic “perfect storm” of epidemics within a pandemic. A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized.

A report by the Agency for Healthcare Research and Quality suggested existing evidence on continuous positive airway pressure devices is not robust enough to be clinically meaningful.

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

Briana Contreras, associate editor of Managed Healthcare, speaks with Linda Matthews, president of BioCare, a leading specialty distributor of life-saving therapies, in this week's episode of Tuning In to the C-Suite podcast. The two discussed the evolution of these therapies over the last decade and most importantly how to expand and diversify a healthcare business.

Many people don't understand their insurance benefits. Hospitals and other providers should proactively explain coverage and out-of-pocket expenses.

The prevalence of smoking among African American young adults “catches up” with other groups despite the low rate among Black youth. The ban on menthol may affect this and other aspects of smoking patterns among Black Americans.

Treating insomnia with commonly prescribed, older generation medications increases health care resource utilization and costs in patients with comorbid conditions.

The AstraZeneca drug is the first SGLT2 inhibitor approved for chronic kidney disease regardless of whether the patient has diabetes.

Oncology Analytics senior vice president Laura Bobolt discusses the new indication for Trodelvy and other matters.

Chemo in combination with immunotherapy was preferable to immunotherapy alone in patients with a mutation of the KRAS gene and high levels of programmed cell death ligand 1, according to findings reported in JAMA Oncology.

Global drug spending — excluding COVID-19 vaccines — is expected to reach an estimated $1.6 trillion by 2025, a new report says.

The antibody-conjugate is also approved as a treatment for metastatic triple negative breast cancer.

The jury is still out, but the evidence is accumulating that people with HIV with comorbidities such as diabetes may be at greater risk for hospitalization from COVID-19.

Improvements in prevention toward HIV is starting in Texas through Texas Health Action. The health organization is creating a virtual HIV prevention service available toward HIV care and gender affirming care in rural areas.

As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.

A recent study from American Accounting Association finds health insurance companies are overestimating costs associated with patient care to avoid triggering rebate provisions in the Affordable Care Act.

The administration gets a A-, B+ on most healthcare matters from Marc Samuels, CEO of ADVI and a member of the MHE editorial advisory board.